These results suggest that targeting adipose tissue CCL5/CCR5-mediated signaling could have therapeutic potential for controlling the development of obesity-associated adipose tissue inflammation and metabolic abnormalities. This evidence concerns the gene CCL5 and obesity due to melanocortin 4 receptor deficiency.